SUPERNUS PHARMAC.DL -,001SUPERNUS PHARMAC.DL -,001SUPERNUS PHARMAC.DL -,001

SUPERNUS PHARMAC.DL -,001

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪1.59 B‬EUR
‪1.19 M‬EUR
‪550.42 M‬EUR
‪52.62 M‬
Beta (1Y)
0.94

About Supernus Pharmaceuticals, Inc.

CEO
Jack A. Khattar
Headquarters
Rockville
Employees (FY)
652
Founded
2005
FIGI
BBG00PX583N6
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005, and is headquartered in Rockville, MD.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange SUPERNUS PHARMAC.DL -,001 stocks are traded under the ticker S49.
SUPERNUS PHARMAC.DL -,001 is going to release the next earnings report on Aug 6, 2024. Keep track of upcoming events with our Earnings Calendar.
SUPERNUS PHARMAC.DL -,001 revenue for the last quarter amounts to ‪133.13 M‬ EUR despite the estimated figure of ‪135.15 M‬ EUR. In the next quarter revenue is expected to reach ‪138.37 M‬ EUR.
Yes, you can track SUPERNUS PHARMAC.DL -,001 financials in yearly and quarterly reports right on TradingView.
S49 net income for the last quarter is ‪1.06 M‬ EUR, while the quarter before that showed ‪−15.11 M‬ EUR of net income which accounts for 107.04% change. Track more SUPERNUS PHARMAC.DL -,001 financial stats to get the full picture.
No, S49 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, S49 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SUPERNUS PHARMAC.DL -,001 stock right from TradingView charts — choose your broker and connect to your account.
S49 reached its all-time high on Jun 29, 2018 with the price of 52.0 EUR, and its all-time low was 3.4 EUR and was reached on Apr 25, 2013. View more price dynamics on S49 chart.
See other stocks reaching their highest and lowest prices.
As of May 9, 2024, the company has 652.00 employees. See our rating of the largest employees — is SUPERNUS PHARMAC.DL -,001 on this list?
We've gathered analysts' opinions on SUPERNUS PHARMAC.DL -,001 future price: according to them, S49 price has a max estimate of 39.68 EUR and a min estimate of 35.06 EUR. Watch S49 chart and read a more detailed SUPERNUS PHARMAC.DL -,001 stock forecast: see what analysts think of SUPERNUS PHARMAC.DL -,001 and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SUPERNUS PHARMAC.DL -,001 EBITDA is ‪89.01 M‬ EUR, and current EBITDA margin is 16.17%. See more stats in SUPERNUS PHARMAC.DL -,001 financial statements.